Interlagos Capital

New York, New York
Firm Location:New York, New York • Los Angeles, California
Investor Firms That Co-Invest with Interlagos Capital
Interlagos Capital Team
Photo of Pablo Lubroth, General Partner at Interlagos Capital
Pablo Lubroth
Interlagos Capital·General Partner
Sweet spot: $2.8M
Range: $500K - $5.0M
Investors in London, Investors in New York (NY)
Investors in Pharmaceuticals (Seed), Investors in BioTech (Series B), Investors in Consumer Health (Seed), Investors in AI (Series A), Investors in Consumer Health (Series B), Investors in Direct-to-Consumer (DTC) (Series A), Investors in Hardware (Seed), Investors in Diverse Investors (Other Lists), Investors in Hardware (Series B), Investors in Hardware (Series A), Investors in Consumer Health (Series A), Investors in Hardware (Series B), Investors in AI (Series B), Investors in Consumer Health (Seed), Investors in Consumer Health (Seed), Investors in AI (Series A), Investors in AI (Seed), Investors in Hardware (Seed), Investors in Hardware (Seed), Investors in Consumer Health (Series A), Investors in Hardware (Series B), Investors in Consumer Health (Series A), Investors in AI (Series A), Investors in Hardware (Series A), Investors in Hardware (Series A), Investors in Consumer Health (Series B), Investors in Hardware (Pre-seed), Investors in Consumer Health (Series B), Investors in AI (Series B), Investors in AI (Series B), Investors in Angel, Scout, and Solo-Capitalists (Other Lists), Investors in Direct-to-Consumer (DTC) (Seed), Investors in Direct-to-Consumer (DTC) (Seed), Investors in Direct-to-Consumer (DTC) (Series B), Investors in Direct-to-Consumer (DTC) (Series A), Investors in Direct-to-Consumer (DTC) (Series B), Investors in Direct-to-Consumer (DTC) (Series B), Investors in Direct-to-Consumer (DTC) (Seed), Investors in Direct-to-Consumer (DTC) (Series A), Investors in Hardware (Pre-seed), Investors in Direct-to-Consumer (DTC) (Pre-seed), Investors in Consumer Health (Pre-seed), Investors in Hardware (Pre-seed), Investors in AI (Pre-seed), Investors in AI (Pre-seed), Investors in Consumer Health (Pre-seed), Investors in Consumer Health (Pre-seed), Investors in AI (Pre-seed), Investors in Direct-to-Consumer (DTC) (Pre-seed), Investors in Direct-to-Consumer (DTC) (Pre-seed), Investors in AI (Seed), Investors in AI (Seed), Investors in BioTech (Seed), Investors in Pharmaceuticals (Series B), Investors in BioTech (Series A), Investors in Pharmaceuticals (Series A), Investors in BioTech (Seed), Investors in BioTech (Seed), Investors in New York City (Other Lists), Investors in Pharmaceuticals (Seed), Investors in Pharmaceuticals (Seed), Investors in BioTech (Series A), Investors in BioTech (Series A), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series B), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series B), Investors in Pharmaceuticals (Series B), Investors in Pharmaceuticals (Series B), Investors in London (Other Lists), Investors in Digital Health (Series B), Investors in Digital Health (Series B), Investors in Digital Health (Series A), Investors in Digital Health (Seed), Investors in Digital Health (Seed), Investors in Digital Health (Series A), Investors in Digital Health (Series B), Investors in DeepTech (Seed), Investors in DeepTech (Series A), Investors in DeepTech (Series B), Investors in DeepTech (Series A), Investors in DeepTech (Seed), Investors in DeepTech (Series B), Investors in DeepTech (Series A), Investors in DeepTech (Seed), Investors in Pharmaceuticals (Pre-seed), Investors in DeepTech (Series B), Investors in DeepTech (Pre-seed), Investors in Digital Health (Pre-seed), Investors in BioTech (Pre-seed), Investors in Pharmaceuticals (Pre-seed), Investors in Pharmaceuticals (Pre-seed), Investors in Therapeutics (Series A), Investors in Digital Health (Pre-seed), Investors in BioTech (Pre-seed), Investors in Digital Health (Pre-seed), Investors in Therapeutics (Seed), Investors in Therapeutics (Series A), Investors in Therapeutics (Seed), Investors in Therapeutics (Series A), Investors in DeepTech (Pre-seed), Investors in Therapeutics (Pre-seed), Investors in Therapeutics (Seed), Investors in Therapeutics (Series B), Investors in Therapeutics (Series B), Investors in Therapeutics (Pre-seed), Investors in DeepTech (Pre-seed), Investors in Therapeutics (Pre-seed), Investors in Therapeutics (Series B), Investors in BioTech (Pre-seed), Investors in Digital Health (Series A), Investors in Digital Health (Seed)
Photo of Achal Upadhyaya, Managing Partner at Interlagos Capital
Achal Upadhyaya
Interlagos Capital·Managing Partner
Sweet spot: $10.0M
Range: $4.0M - $40.0M
Investors in United States